Gene-Edited immune cells take on Hard-to-Treat cancers
NCT ID NCT05795595
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new treatment called CTX131 for adults with advanced solid tumors that have not responded to standard therapies. The treatment uses donor immune cells that are gene-edited to target a protein called CD70 found on cancer cells. The study enrolled 19 people with several cancer types to check safety and whether the tumors shrink.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site 1
Nashville, Tennessee, 37203, United States
-
Research Site 2
St Louis, Missouri, 63110, United States
-
Research Site 3
Duarte, California, 91010, United States
-
Research Site 4
Durham, North Carolina, 27710, United States
-
Research Site 5
Houston, Texas, 77030, United States
-
Research Site 6
Boston, Massachusetts, 02215, United States
-
Research Site 7
Chicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rouse the immune system against pancreatic cancer?
- A sound wave that could expose hidden pancreatic cancer?
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?